YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Harmony Biosciences Holdings (NasdaqGM:HRMY) plans to present new Phase 3 data on its investigational therapy HBS-301 at European Narcolepsy Days. The company aims to share results from ongoing late-stage trials in narcolepsy and idiopathi…
Harmony Biosciences Holdings has delivered a 1 year share return that catches the eye, which naturally raises a question for investors who focus on earnings. Is the current US$39.34 price a fair reflection of what the business is generatin…
Harmony BioSciences (HRMY) has several underappreciated value drivers supporting its long-term growt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?…
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly l…
Harmony Biosciences PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301,…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks continue to attract investor attention as managed care providers, pharmaceutical companies, biotech…
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 6.2% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading…
A month has gone by since the last earnings report for Harmony Biosciences Holdings, Inc. (HRMY). Shares have added about 12.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next e…
Harmony Biosciences PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydroch…
Harmony Biosciences PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global He…
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surge…
ANI Pharmaceuticals ANIP reported second-quarter 2026 adjusted EPS of $2.21, beating the Zacks Consensus Estimate of $2.01. The reported figure rose 23% year over year, driven by higher sales during the quarter. Quarterly revenues totaled…
Shares of Outlook Therapeutics OTLK have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company's sole product, Lytenava, which is approved for the treatment of patien…
Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader…
Harmony Biosciences Holdings, Inc. recently reported second-quarter 2026 results showing net income of US$75.43 million, up from US$39.78 million a year earlier, with basic earnings per share from continuing operations rising to US$1.30 fr…
Immunocore Holdings plc IMCR incurred a loss of 2 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 1 cent per share. In the year-ago quarter, the company had incurred a loss of 20 cents pe…
Ocugen OCGN reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development spending weighed on results. Revenues rose 8.4…
BioMarin Pharmaceutical BMRN reported second-quarter 2026 adjusted earnings of $1.20 per share, which beat the Zacks Consensus Estimate of 96 cents. However, the bottom line declined 16.7% year over year from $1.44. Total revenues were $98…
Puma Biotechnology PBYI reported second-quarter 2026 adjusted earnings of 19 cents per share, beating the Zacks Consensus Estimate of 10 cents. In the year-ago quarter, the company had reported adjusted earnings of 15 cents per share. Tota…
Intellia Therapeutics NTLA incurred a second-quarter 2026 loss of 80 cents per share, in line with the Zacks Consensus Estimate. The loss narrowed 18.4% from the loss of 98 cents per share in the year-ago quarter. Intellia's total revenues…
Insmed INSM reported an adjusted loss of 52 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 69 cents. The adjusted figure excluded a non-cash gain of $99.8 million tied to a change in…
Xenon Pharmaceuticals XENE reported a loss of $1.11 per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.16 per share. The company had incurred a loss of $1.07 per share in the year-ago quarte…
Iovance Biotherapeutics IOVA incurred a second-quarter 2026 loss of 11 cents per share, narrower than the Zacks Consensus Estimate of a loss of 17 cents. In the year-ago quarter, the company reported a loss of 33 cents. Total revenues for…
The healthcare sector has quietly regained momentum in 2026, with the benchmark State Street Health Care Select Sector SPDR ETF (XLV) advancing 7.1% year to date as of Aug. 6. Investors have increasingly turned to the sector for its defens…
For Immediate Release Chicago, IL – August 7, 2026 – Stocks in this week's article TD SYNNEX CORP SNX, Ameriprise Financial AMP, Harmony Biosciences HRMY and Newell Brands NWL 4 Stocks Trading Near 52-Week Highs with More Upside Potential…
Perrigo PRGO reported second-quarter 2026 All In adjusted earnings per share (EPS) of 50 cents, which beat the Zacks Consensus Estimate of 31 cents. The reported figure declined 12.3% year over year owing to lower sales volumes and the car…
Viatris VTRS delivered second-quarter 2026 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 62 cents. The company reported adjusted earnings of 62 cents in the year-ago quarter. Total revenues were $3.76…
Editas Medicine EDIT incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter. Coll…
Immunovant IMVT incurred first-quarter fiscal 2027 net loss of 75 cents per share, wider than the Zacks Consensus Estimate of a loss of 66 cents. The company had reported a loss of 71 cents per share in the year-ago quarter. Excluding stoc…
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 23 cents. The company had incurred a loss of 41 cents per share in the year-ago quarte…
ADMA Biologics, Inc. ADMA reported second-quarter 2026 earnings of 16 cents per share, which matched the Zacks Consensus Estimate and rose from 14 cents in the year-ago quarter. Revenues grew 2.0% year over year to $124.4 million but misse…
Investors generally consider a stock's 52-week high a good criterion for an entry or exit point. Stocks touching new 52-week highs are often predisposed to profit-taking, resulting in pullbacks and trend reversals. Moreover, given the high…
United Therapeutics UTHR reported second-quarter 2026 earnings per share (EPS) of $7.27, beating the Zacks Consensus Estimate of $6.82. Bottom line increased 13.4% year over year. United Therapeutics markets four products for pulmonary art…
Harmony Biosciences PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual…